RAPT Therapeutics, Inc.RAPTNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank14
3Y CAGR-37.6%
5Y CAGR-9.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-37.6%/yr
Annual compound
5Y CAGR
-9.1%/yr
Recent deceleration
Percentile
P14
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | 6.15% |
| 2023 | 50.56% |
| 2022 | 17.72% |
| 2021 | 25.28% |
| 2020 | 30.29% |
| 2019 | 9.89% |
| 2018 | 24.00% |
| 2017 | 0.00% |